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PURPOSE. We have previously used in vivo corneal confocal microscopy (IVCCM) to
demonstrate significant alterations in the corneal epithelial cells, stromal keratocytes, and
subbasal nerves in young patients with type 1 diabetes mellitis (T1DM), especially those with
diabetic retinopathy (DR). We have evaluated the change in corneal cellular and subbasal
nerve morphology over 2 years in young patients with T1DM with or without DR.
METHODS. A total of 19 patients with T1DM, without (n ¼ 12) and with (n ¼ 7) DR and 19 age-
and sex-matched healthy control subjects underwent quantification of corneal cellular and
subbasal nerve plexus morphology by using IVCCM at baseline and after 2 years.
RESULTS. There was no significant change in corneal basal epithelial, posterior stromal
keratocyte, or endothelial cell densities over 2 years. However, there was a significant
reduction in corneal nerve branch (P ¼ 0.03) and total nerve branch density (P ¼ 0.04) in
patients without DR and a significant reduction in corneal nerve fibre density (P ¼ 0.004) in
those with DR.
CONCLUSIONS. IVCCM can detect a progressive loss of corneal nerve fibers in young patients
with T1DM and may allow the identification of individuals at risk of neuropathy progression
for more active risk factor reduction.
Keywords: corneal confocal microscopy, type 1 diabetes mellitus, follow-up
Type 1 diabetes mellitus (T1DM) occurs in around 10% of allpeople with diabetes, affecting 20 million people world-
wide, and the prevalence of newly diagnosed cases is predicted
to increase by 0.24% to 0.30% over the next 5 to 15 years.1
Microvascular complications can occur in young people with
T1DM,2–4 and diabetic retinopathy (DR) is considered to be the
earliest and most common complication.5,6
Optical coherence tomography (OCT) has shown reduced
thickness of the retinal nerve fiber and ganglion cell layers in
children with T1DM without retinopathy, which is suggestive
of early neuronal damage.6–8 Furthermore, in vivo corneal
confocal microscopy (IVCCM), a rapid noninvasive ophthalmic
imaging technique has also been shown to identify early
corneal cellular and nerve fiber pathology in children and
adolescents with T1DM,9 adults with T1DM without neurop-
athy,10 or retinopathy or microalbuminuria.11 Furthermore,
reduced corneal nerve fiber length predicts the development of
clinical diabetic neuropathy12 and the development or wors-
ening of retinopathy.13 This early corneal nerve fiber damage
has been attributed to elevated hemoglobin A1c (HbA1c) and
triglycerides and a lower high-density lipoprotein (HDL).14
Corneal nerve fiber regeneration has been observed after
combined pancreas and kidney transplantation15 and after
treatment with the novel nonerythropoietic peptide ARA
290.16 Based on our previous study showing reduced corneal
nerve fiber parameters in young adolescents with T1DM with
and without DR,9 the present case-control follow-up study
assessed the progression of corneal cellular and nerve fiber
abnormalities in these young T1DM patients.
METHODS
Study Subjects
All subjects were attending the Ophthalmology Department,
Faculty of Medicine, University of Debrecen. Ethical approval
was obtained from the University of Debrecen Ethics Commit-
tee (number 4701A-2016), and all subjects provided written
informed consent in accordance with the Declaration of
Helsinki. In case of children under 18 years of age, written
informed consent was obtained from their parents or legal
guardians.
At baseline, DR status was graded in T1DM patients
according to the International Clinical Diabetic Retinopathy
Disease Severity Scale by using fundus photography. Patients
were classified into no DR (NDR) and DR groups and compared
with age- and sex-matched healthy volunteers (CNDR and CDR)
without diabetes or history of systemic inflammatory or ocular
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diseases. Exclusion criteria included contact lens wear and
previous intraocular surgery.
Clinical and Ophthalmologic Investigations
Participants with T1DM underwent a comprehensive medical
examination that included measurements of HbA1c, serum
lipids, estimated glomerular filtration rate (eGFR), blood
pressure, and microalbuminuria. Ophthalmologic examination
included slit-lamp examination, dilated fundus photography,
intraocular pressure measurement, and IVCCM. Additional
neuropathy tests and tear layer assessments were not
performed.
In Vivo Corneal Confocal Microscopy
In 2014, we undertook IVCCM in 28 young patients with
T1DM, with (n ¼ 10) and without (n ¼ 18) DR.9 Nineteen of
these T1DM patients with (n ¼ 7) and without (n ¼ 12)
retinopathy who had continued to be seen by their diabetol-
ogist under standard clinical care, agreed to be reassessed in
2016. IVCCM analysis was performed using the Heidelberg
Retina Tomograph III Rostock Cornea Module (HRT III RCM;
Heidelberg Engineering GmbH, Heidelberg, Berlin, Germany).
Local anesthetic (tetracaine hydrochloride 0.5%) was applied,
and the subject was asked to focus on a distant target before
scanning the central cornea. The right eye of normal controls
and NDR patients was used for analysis, and in patients with
DR, only the eligible eye (no previous intraocular surgery) was
used for analysis. Section and volume scans were recorded
from the basal epithelium anterior to Bowman’s layer, subbasal
nerve plexus (SBP), posterior stroma anterior to Descemet’s
membrane and endothelial cells (volume scans from the
epithelium to the endothelial cells, and good quality section
scans at the missing depths).
Image Selection
Three representative images of good quality were chosen from
the basal epithelium, SBP, posterior stromal (keratocytes), and
endothelial cell layers. A region of interest (ROI) was chosen
from each cell layer containing at least 50 cells.
Image Analysis
The ROI area was 0.003 6 0.007 mm2 for the epithelium,
0.100 6 0.009 mm2 for the stromal keratocyte layer, and 0.028
6 0.009 mm2 for the endothelium. Focus position was 7 6 3
lm for the epithelium, 65 6 11 lm for the keratocytes, and
564 6 17 lm for the endothelium. The cells were marked
manually and the instrument-based software (Heidelberg Eye
Explorer software; Heidelberg Engineering GmbH, Heidelberg,
Berlin, Germany) automatically calculated cell densities (cells/
mm2). SBP morphology was quantified using automated
software (ACCMetrics version 2.0; University of Manchester,
Manchester, UK).17 The following parameters were quantified:
corneal nerve fiber density (CNFD), the number of nerve
fibers/mm2; corneal nerve branch density (CNBD), the number
of primary branch points on the main nerve fibrers/mm2;
corneal nerve fiber length (CNFL), the total length of nerves
mm/mm2; corneal nerve fiber total branch density (CNTBD),
the total number of branch points/mm2; corneal nerve fibre
area (CNFA), the total nerve fibre area mm2/mm2; and corneal
nerve fiber width (CNFW), the average nerve fiber width mm/
mm2.
Statistical Analysis
The statistical analysis was performed using SPSS (version 22.0)
and MedCalc (version 18.2.1) statistical programs for Windows.
Descriptive data are shown as mean 6 standard deviation (SD)
and 95% confidence interval (CI). Student’s t-test was used to
determine the differences between patients with T1DM and
controls. A paired t-test was used to compare corneal cellular
and nerve morphology between baseline and follow-up. For
univariate analysis, the v2 test and for bivariate datasets
Pearson correlation test was used. Case-control analysis was
performed with statistical significance criterion set at P < 0.05
in all cases.
RESULTS
Demographic and Clinical Data
The demographic data are summarized in Table 1, and the
clinical metabolic data of T1DM patients with and without DR
are shown in Table 2. Total cholesterol decreased (P¼ 0.04) in
the DR group, while triglycerides, HDL cholesterol, eGFR,
blood pressure, and microalbuminuria showed no significant
change over 2 years.
Corneal Cell Densities
There was no significant change in epithelial, keratocyte and
endothelial cell densities, and central corneal thickness in
patients with T1DM with and without DR compared to control
subjects (Table 3; Fig. 1, 2).
Corneal SBP
There was no significant difference in any corneal nerve
parameter between T1DM patients without DR and control
subjects. CNFL was significantly lower in T1DM patients with
DR compared to control subjects (P ¼ 0.002). Over 2 years,
TABLE 1. Demographics of Control Subjects and Patients with T1DM
Groups
CNDR,
n ¼ 12
Baseline NDR,
n ¼ 12
Follow-up NDR,
n ¼ 12
CDR,
n ¼ 7
Baseline DR,
n ¼ 7
Follow-up DR,
n ¼ 7
Age, y
Mean 17 14 16 37 34 36
6SD 4 3 3 6 6 6
Sex
Male 4 4 4 6 6 6
Female 8 8 8 1 1 1
CNDR, controls for T1DM patients without DR (NDR); CDR, controls for T1DM patients with DR expressed as mean 6 SD.
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there was a significant decrease in CNBD (P ¼ 0.03) and
CNTBD (P ¼ 0.04), with a trend for reduction in CNFA (P ¼
0.08) and CNFW (P ¼ 0.07) in the NDR group (Fig. 3). There
was a significant reduction in CNFD (P¼0.04) in the DR group
(Table 4).
Correlation Analysis
In patients with T1DM, serum triglycerides correlated inversely
with CNFW (r¼0.339, P¼ 0.04), but there was no significant
correlation between the duration of diabetes, HbA1c, serum
triglycerides, HDL, and eGFR with any other corneal nerve
parameters (P > 0.05).
DISCUSSION
IVCCM is a rapid, noninvasive ophthalmic imaging technique
that detects subclinical nerve damage18 and predicts the
development of neuropathy in adults with diabetes.12,19 In
two large pooled analyses, a normative age range20 and a good
diagnostic ability for diabetic peripheral neuropathy have been
established.21 A reduction in basal epithelial and intermediate
cell density was related to diabetes duration and diastolic blood
pressure, while reduced CNFD and CNFL were related to
HbA1c in adults with T1DM and type 2 diabetes mellitus
(T2DM).22 Additionally, CNFD, CNDB, and CNFL were reduced
in adults with T2DM with and without DR, while epithelial,
FIGURE 1. Corneal cell densities in controls compared to T1DM over 2 years. Patients with T1DM without (NDR) and with (DR) retinopathy
compared to controls (CNDR and CDR) at baseline and follow-up. The basal epithelial cell (A), keratocyte (B), and endothelial cell (C) densitites
measured with in vivo corneal confocal microscopy (IVCCM). Controls (white bars), T1DM baseline (gray bars), and follow up (black bars). Box
and whiskers show the mean values with interquartile range.
TABLE 2. Clinical and Metabolic Data of T1DM Patients With (DR) and Without (NDR) Retinopathy, at Baseline and Follow-up
Baseline NDR, n ¼ 12 Follow-up NDR, n ¼ 12 P* Baseline DR, n ¼ 7 Follow-up DR, n ¼ 7 P*
Duration of DM, y
Mean 6 9 22 24
6SD 3 3 7 7
HbA1c, % 0.278 0.894
Mean 7.82 8.14 8.29 8.43
6SD 1.09 1.22 0.93 2.05
95% CI 7.1–8.5 7.4–8.9 7.4–9.2 6.5–10.3
Cholesterol, mmol/L 0.123 0.042
Mean 4.03 4.37 5.23 5.10
6SD 0.51 0.73 0.59 1.35
95% CI 3.7–4.4 3.9–4.9 4.3–6.2 1.7–8.5
Triglycerides, mmol/L 0.067 0.317
Mean 0.83 0.73 2.43 1.45
6SD 0.27 0.18 1.80 0.78
95% CI 0.7 to 1.0 0.6 to 0.9 2.0 to 6.9 5.5 to 8.4
HDL cholesterol, mmol/L 0.320 0.578
Mean 1.73 1.84 1.93 1.85
6 SD 0.25 0.28 1.21 0.07
95% CI 1.6 to 1.9 1.7 to 2.0 1.1 to 4.9 1.2 to 2.5
eGFR, mL/min/1.73m2 0.801 0.943
Mean >90 in all patients >90 in all patients 81.71 80.71
6SD 21.92 24.57
95% CI 61.4 to 101.9 57.9 to 103.4
Hypertension 0 0 2 2
Insulin pump users 5 5 0 0
Microalbuminuria 0 0 2 2
* P values, paired t-test to determine the differences between baseline and follow-up.
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FIGURE 2. Corneal cell identification using Heidelberg Retina Tomograph instrument-based software. Section and volume scans from the corneal
cell layers in the same patient’s same eye with T1DM with DR at follow-up, at baseline (A) and after 2 years (B).
TABLE 3. Corneal Cell Densities and Central Corneal Thickness in Patients with T1DM Compared to Control Subjects at Baseline and Follow-up
Groups
CNDR,
n ¼ 12
Baseline NDR,
n ¼ 12
Follow-up NDR,
n ¼ 12
CDR,
n ¼ 7
Baseline DR,
n ¼ 7
Follow-up DR,
n ¼ 7
Epithelial cell density, cells/mm2
Mean 6,248.33 6,333.72 6,514.74 6,327.58 6,048.71 5,743.95
6SD 639.62 1,290.25 877.19 650.76 671.17 772.87
95% CI 5,818.6–6,678.0 5,513.9–7,153.5 5925.4–7104.1 5,783.5–6,871.6 5428.0–6669.5 5,029.2–6,458.7
P*† 0.845* 0.701† 0.894* 0.446†
Keratocyte cell density, cells/mm2
Mean 475.73 414.62 466.40 385.00 439.38 472.40
6SD 168.97 115.21 140.48 70.14 148.27 105.18
95% CI 362.2–5,889.2 337.2–492.0 372.0–560.8 311.4–458.6 302.3–576.5 375.1–569.7
P 0.334* 0.356† 0.668* 0.639†
Endothelial cell density, cells/mm2
Mean 2,977.95 2,980.48 2,980.70 2,384.50 2,343.53 2,652.37
6SD 406.53 292.12 490.10 442.18 445.26 464.62
95% CI 2,551.3–3,404.6 2,736.3–3,224.7 2,604.0–3,357.4 1,680.9–3,088.1 1,790.6–2,896.4 2,075.5–3,229.3
P 0.989* 0.999† 0.429* 0.315†
Central corneal thickness, lm
Mean 551.54 562.067 560.00 545.06 560.46 576.86
6SD 28.21 25.48 34.89 20.21 23.55 33.28
95% CI 532.6–570.5 545.8–578.3 538.4–582.7 528.1–562.0 538.7–582.2 546.1–607.6
P 0.358* 0.907† 0.196* 0.308†
CNDR, controls for NDR group; CDR, controls for DR group.
* P value determined using Student’s t-test to compare the baseline T1DM groups with controls.
† P value determined using paired t-test to determine the difference between baseline and follow-up.
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FIGURE 3. Original and annotated representative images of the SBP by using ACCMetrics software. SBP morphology of a patient with T1DM with
DR at baseline (A, B) and after 2 years (C, D) compared with a healthy age- and sex-matched subject (E, F). Red lines (main fibers), blue lines
(branches), and green points (branch points) showing reduced corneal nerves at baseline with a further reduction at follow up.
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stromal, and endothelial cell densities were only reduced in
patients with DR.23 Furthermore, in T1DM we have shown an
early reduction in corneal nerve fibers in patients without DR
or microalbuminuria.24
IVCCM can be undertaken reliably and with good repro-
ducibility in children with T1DM.25 An initial study in children
and adolescents with T1DM showed no difference in corneal
nerve morphology.26 Although, more recently we have shown
a reduction in epithelial and endothelial cell densities and a
reduction in CNDB and CNFL in adolescent T1DM patients
without DR and a further reduction in CNFD and CNBD in
those with DR.9
There are no longitudinal studies assessing change in
corneal cellular morphology, and only one previous study has
assessed nerve fiber morphology over time in adults with
T1DM, showing a reduction in CNFD and CNBD, which was
related to HbA1c.
14 This is the first longitudinal study in young
adolescents with T1DM and it shows no significant change in
epithelial, stromal, and endothelial cell densities over 2 years.
With regard to early nerve fiber alterations, previous studies
have shown a reduction in corneal and retinal nerve fiber
parameters prior to the development of retinopathy13,27 and a
relatively greater reduction in CNFL in patients with T1DM
compared to T2DM.28 In the present study over 2 years, there
was a significant decrease in the distal branches (CNBD and
CNTBD) in young patients with T1DM without DR and a
reduction in more proximal nerves (CNFD) in patients with
DR. This is consistent with a retrograde process of neurode-
generation that has been demonstrated recently with a greater
reduction in the inferior whorl compared to central CNFL.29
The diagnostic ability of IVCCM may be further enhanced by
assessing the inferior whorl or using wide-area mosaics, which
take into account both proximal and distal corneal nerve
morphology.30,31
Multiple pathogenetic mechanisms, including advanced
glycation, increased flux through the sorbitol pathway, and
oxidative stress, have been implicated in the development of
diabetic neuropathy.32 Experimental studies using a combina-
tion of menhaden oil, a-lipoic acid, and enalapril have been
shown to ameliorate oxidative and inflammatory stress and
improve distal corneal nerve morphology.33 Several recent
studies have shown early corneal nerve fiber regeneration in
T1DM patients after combined pancreas and kidney transplan-
tation,15 T2DM patients treated with the novel nonerythro-
poietic peptide ARA 290,16 and T1DM patients treated with
omega-3 polyunsaturated fatty acid supplementation.34 Fur-
thermore, a recent study in patients with T2DM has shown that
multifactorial intervention that reduces HbA1c, blood pressure,
and weight results in corneal nerve fiber regeneration.35
Indeed, a change in corneal nerve morphology may prove to
be a more sensitive end-point to assess the benefits of risk
factor reduction on microvascular complications, given that
the recent Adolescent Type 1 Diabetes Cardio-Renal Interven-
tion Trial showed no change in albumin excretion and
TABLE 4. SBP Morphology in Control Subjects and Patients with T1DM at Baseline and Follow-up
Groups
CNDR,
n ¼ 12
Baseline NDR,
n ¼ 12
Follow-up NDR,
n ¼ 12
CDR,
n ¼ 7
Baseline DR,
n ¼ 7
Follow-up DR,
n ¼ 7
CNFD, no./mm2
Mean 13.97 10.81 10.76 16.93 14.58 6.60
6SD 7.36 11.09 9.26 4.45 7.36 3.59
95% CI 9.0–18.9 0.5–21.1 1.0–20.5 13.2–20.7 5.4–23.7 2.8–10.4
P 0.530* 0.173† 0.485* 0.043†
CNBD, no./mm2
Mean 12.59 12.36 6.25 16.66 16.25 6.25
6SD 7.48 9.50 5.43 5.59 12.79 5.43
95% CI 7.6–17.6 3.6–21.2 0.5–11.9 11.9–21.3 0.4–32.1 0.5–11.9
P 0.196* 0.029† 0.936* 0.114†
CNFL, mm/mm2
Mean 10.33 10.67 8.58 12.52 8.43 7.71
6SD 3.19 4.98 3.49 0.85 2.96 1.44
95% CI 8.2–12.5 6.1–15.3 6.2–10.9 11.8–13.2 5.7–11.2 6.4–9.1
P 0.494* 0.153† 0.002* 0.573†
CNTBD, no./mm2
Mean 28.50 28.82 20.36 31.44 21.73 20.83
6SD 12.93 14.44 10.67 10.64 13.28 12.15
95% CI 19.8–37.2 15.5–42.2 13.2–7.5 22.5–40.3 9.5–34.0 9.6–32.1
P 0.214* 0.035† 0.140* 0.898†
CNFA, mm2/mm2
Mean 0.0047 0.0057 0.0047 0.0053 0.0046 0.0051
6SD 0.0020 0.0013 0.0012 0.0001 0.0017 0.0019
95% CI 0.003–0.006 0.005–0.007 0.004–0.006 0.005–0.006 0.003–0.006 0.003–0.007
P 0.160* 0.086† 0.404* 0.694†
CNFW, mm/mm2
Mean 0.0235 0.0240 0.0260 0.0220 0.0240 0.0250
6SD 0.0028 0.0031 0.0038 0.0019 0.0031 0.0044
95% CI 0.022–0.025 0.021–0.027 0.023–0.028 0.021–0.024 0.021–0.028 0.021–0.028
P 0.839* 0.074† 0.239* 0.760†
CNDR, controls for T1DM without NDR; CDR, controls for T1DM with DR.
* P values determined with Student’s t-test to compare baseline T1DM to controls.
† P values determined with paired t-test to determine the difference between baseline and follow-up.
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retinopathy in children treated with a statin and ACE inhibitor
over 4 years.36
A limitation of the current study is the relatively small
number of patients assessed at follow-up. However, this is the
first longitudinal study of young adolescents with T1DM and it
shows an early and progressive reduction in corneal nerve
morphology. We believe these data support the potential utility
of corneal nerve morphology quantification to assess the
benefits of new therapies for diabetic neuropathy.
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